Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus PT from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given an average rating of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $43.17.

ORKA has been the subject of several analyst reports. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, December 20th. TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, Leerink Partners started coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $19.01 on Friday. The business’s 50-day moving average price is $23.74. The firm has a market capitalization of $665.33 million, a P/E ratio of -3.04 and a beta of 0.78. Oruka Therapeutics has a 52 week low of $18.20 and a 52 week high of $53.88.

Institutional Trading of Oruka Therapeutics

Several institutional investors have recently modified their holdings of ORKA. FMR LLC acquired a new stake in shares of Oruka Therapeutics in the third quarter worth approximately $114,763,000. RTW Investments LP purchased a new position in Oruka Therapeutics in the 3rd quarter valued at $45,359,000. Franklin Resources Inc. acquired a new stake in Oruka Therapeutics during the 3rd quarter worth $17,661,000. Braidwell LP purchased a new stake in shares of Oruka Therapeutics during the third quarter worth $12,640,000. Finally, Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at about $12,614,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.